DUBLIN, June 20, 2022 /PRNewswire/ -- The "Renal Biomarkers Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to
ResearchAndMarkets.com's offering.
The global renal biomarkers market reached a value of US$ 1.13 billion in 2021. Looking forward, the market is projected to reach a value of US$ 1.88 billion by 2027, exhibiting a CAGR of 8.70% during 2022-2027. Keeping in mind the uncertainties of COVID-19, the analyst is continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different End-use sectors. These insights are included in the report as a major market contributor. Renal biomarkers are cells, proteins, lipids, microRNAs, genes, metabolites, or proteomic patterns present on a urinalysis. They assist in determining the glomerular filtration rate (GFR) of kidneys to analyze their proper functioning and evaluating pathogenic processes or pharmacological responses to therapeutic interventions. As they also aid in predicting disease progression and computing drug dosage, renal biomarkers find extensive applications in hospitals and diagnostic laboratories across the globe.
Moreover, renal biomarkers, including blood urea nitrogen (BUN), serum creatinine (SCr), urinary albumin/protein and volume excretion, are used in the diagnosis of chronic kidney disease (CKD) and monitoring of the disease. Besides this, there is a growing interest of industry investors in novel single biomarkers and process-specific biomarker panels in human renal diseases around the world. These novel biomarkers provide vital diagnostic and prognostic information and help predict response to the treatment of glomerulopathies, acute kidney injury (AKI), and autosomal dominant polycystic kidney disease (ADPKD). Apart from this, renal biomarkers are becoming accessible and feasible in all-sized laboratories. This, along with the development and integration of genomics, epigenetics, transcriptomics, proteomics, and metabolomics, is positively influencing the market. Some of the other factors, such as the burgeoning healthcare industry, the rising geriatric population, and the increasing number of clinical trials for CKD worldwide, are anticipated to facilitate the growth of the market. Key Questions Answered in This Report
How has the global renal biomarkers market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global renal biomarkers market? What are the key regional markets?
What is the breakup of the market based on the biomarker type?
What is the breakup of the market based on the diagnostic technique?
What is the breakup of the market based on the End-user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global renal biomarkers market and who are the key players?
What is the degree of competition in the industry?
5 Global Renal Biomarkers Market
6 Market Breakup by Biomarker Type
6.2.2.2 Kidney Injury Molecule-1
7 Market Breakup by Diagnostic Technique
7.1 Enzyme-linked Immunosorbent Assay (ELISA)
7.2 Particle-enhanced Turbidimetric Immunoassay (PETIA)
7.4 Chemiluminescent Immunoassay (CLIA)
7.5 Liquid Chromatography Mass Spectrometry (LC-MS)
8 Market Breakup by End User
8.2 Diagnostic Laboratory
9 Market Breakup by Region
12 Porters Five Forces Analysis
14.3 Profiles of Key Players
14.3.1.1 Company Overview
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
For more information about this report visit https://www.researchandmarkets.com/r/uucxxj
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716